Immuneering Corp
IMRX· Nasdaq
Released Aug 5, 2026, before the open
10-Q filed Aug 5, 2026, 36 days after period end · 0001790340-26-000091
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$17.27M | -$14.43M | -$14.08M | -$12.19M |
| EPS Diluted |
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
| -$0.27 |
| -$0.40 |
| -$0.47 |
| -$0.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.